Inaugural bone metastases in non-small cell lung cancer: A specific prognostic entity?

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Deberne, Mélanie ^a   Ropert, Stanislas ^b   Billemont, Bertrand ^b   Daniel, Catherine ^a   Chapron, Jeanne ^b   Goldwasser, François ^b,c  

^a INSTITUT CURIE   (France)

^b Institut Cochin   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Bone metastasis; Lung adenocarcinoma; Skeletal related events; Spinal epidural metastasis

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ADVANCED CANCER; ARTICLE; BONE METASTASIS; CANCER INCIDENCE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DECISION MAKING; FEMALE; HISTOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RISK FACTOR; SPINE METASTASIS; WEIGHT REDUCTION; AGED; BONE NEOPLASMS; FOLLOW UP; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SECONDARY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; C-REACTIVE PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84902543720     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-416     Document Type: Article

References (34)

1. Locher C, Debieuvre D, Coëtmeur D, Goupil F, Molinier O, Collon T, Dayen C, Le Treut J, Asselain B, Martin F, Blanchon F, Grivaux M. Major changes in lung cancer over the last ten years in France: The KBP-CPHG studies. Lung Cancer 2013, 81:32-38. 10.1016/j.lungcan.2013.03.001, 23541463.
2. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006, 12:6243s-6249s. 10.1158/1078-0432.CCR-06-0931, 17062708.
3. Decroisette C, Monnet I, Berard H, Quere G, Le Caer H, Bota S, Audigier-Valette C, Geriniere L, Vernejoux JM, Chouaid C, . Groupe Français de Pneumo-Cancérologie 0601 Team Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational multicenter study (GFPC 0601). J Thorac Oncol 2011, 6(3):576-82. 10.1097/JTO.0b013e318206a1e3, 21270669, Groupe Français de Pneumo-Cancérologie 0601 Team.
4. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550. 10.1056/NEJMoa061884, 17167137.
5. Sugiura H, Yamada K, Sugiura T, Hida T, Mitsudomi T. Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res 2008, 466:729-736. 10.1007/s11999-007-0051-0, 2505203, 18196360.
6. Bae YM, Se-Hoon L, Tae Min K, Dong-Wan K, Seok-Chul Y, Hong Gyun W, Young Whan K, Dae Seog H. Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis. Lung Cancer 2012, 77:572-577. 10.1016/j.lungcan.2012.05.094, 22672969.
7. Weiss RJ, Wedin R. Surgery for skeletal metastases in lung cancer. Acta Orthop 2011, 82(1):96-101. 10.3109/17453674.2011.552779, 3230004, 21281260.
8. Nathan S, Healey JH, Mellano D, Hoang B, Lewis I, Morris CD, Athanasian EA, Boland PJ. Survival in patients operated on for pathologic fracture: implications for end-of-life orthopedic care. J Clin Oncol 2005, 23:6072-6081. 10.1200/JCO.2005.08.104, 16135474.
9. Kagohashi K, Satoh H, Ishikawa H, Ohtsuka M, Sekizawa K. Bone metastasis as the first manifestation of lung cancer. Int J Clin Pract 2003, 57:184-186.
10. Charloux A, Quoix E, Wolkove N, Small D, Pauli G, Kreisman H. The increasing incidence of lung adenocarcinoma: reality or artefact? a review of the epidemiology of lung adenocarcinoma. Int J Epidemiol 1997, 26:14-23. 10.1093/ije/26.1.14, 9126499.
11. Charloux A, Rossignol M, Purohit A, Small D, Wolkove N, Pauli G, Quoix E, Kreisman H. International differences in epidemiology of lung adenocarcinoma. Lung Cancer 1997, 16(2-3):133-143. 10.1016/S0169-5002(96)00623-X, 9152945.
12. Jasmin C, Coleman RE, Coia LR, Capanna R, Saillant G. Daniel E.Roos, Lung Cancer, in " the Textbook of Bone Metastases" 2005, John Wiley and Sons.
13. Kosteva JLC. Incidence and distribution of skeletal metastases in NSCLC in the era of PET. Lung Cancer 2004, 86.
14. Tsuya A, Kurata T, Tamura K, Fukuoka M. Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer 2007, 57:229-232. 10.1016/j.lungcan.2007.03.013, 17451841.
15. Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J, Sung J, Raut M, Oster G. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 2004, 67:390-396. 10.1159/000082923, 15713995.
16. Katagiri H, Takahashi M, Wakai K, Sugiura H, Kataoka T, Nakanishi K. Prognostic factors and a scoring system for patients with skeletal metastasis. J Bone Joint Surg 2005, 87-B:698-703.
17. Forsberg JA, Wedin R, Bauer HC, Hansen BH, Laitinen M, Trovik CS, Keller JO, Bol PJ, Healey JH. External validation of the Bayesian estimated tools for survival ( BETS) models in patients with surgically treated skeletal metastases. BMC Cancer 2012, 12:493. 10.1186/1471-2407-12-493, 3556063, 23098538.
18. Schiff D, O'Neill BP, Suman VJ. Spinal epidural metastasis as the initial manifestation of malignancy: clinical features and diagnostic approach. Neurology 1997, 49:452-456. 10.1212/WNL.49.2.452, 9270576.
19. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Cutsem O, Sergysels R, Mommen P. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients: the European lung cancer working party. J Clin Oncol 1995, 13:1221-1230.
20. Takigawa N, Segawa Y, Okahara M, Maeda Y, Takata I, Kataoka M, Fujii M. Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation. Lung Cancer 1996, 15:67. 10.1016/0169-5002(96)00571-5, 8865124.
21. Wilop S, Crysandt M, Bendel M, Mahnken AH, Osieka R, Jost E. Correlation of C-reactive protein with survival and radiographic response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer. Onkologie 2008, 31:665-670.
22. Berghmans T, Paesmans M, Mascaux C, Martin B, Meert AP, Haller A, Lafitte JJ, Sculier JP. Thyroid transcription factor 1- a new prognostic factor in lung cancer: a meta-analysis. Ann Oncol 2006, 17:1673-1676. 10.1093/annonc/mdl287, 16980598.
23. Muggia FM. Overview of cancer-related hypercalcemia: epidemiology and etiology. Semin Oncol 1990, 17:3-9.
24. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol 2003, 21:3150-3157. 10.1200/JCO.2003.04.105, 12915606.
25. Hirsh V, Tchekmedyian NS, Rosen LS, Zheng M, Hei YJ. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer 2004, 6:170-174. 10.3816/CLC.2004.n.030, 15555218.
26. Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, Brown JE, Coleman RE. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 2008, 3:228-236. 10.1097/JTO.0b013e3181651c0e, 18317064.
27. Zarogoulidis K, Boutsikou E, Zarogoulidis P, Eleftheriadou E, Kontakiotis T, Lithoxopoulou H, Tzanakakis G, Kanakis I, Karamanos NK. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer 2009, 125:1705-1709. 10.1002/ijc.24470, 19521984.
28. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011, 29:1125-1132. 10.1200/JCO.2010.31.3304, 21343556.
29. Scagliotti GV, Hirsh V, Siena S, Henry DH, Woll PG, Manegold C, Solal-Celigny P, Rodriguez G, Krzakowski M, Mehta MD, Lipton L, Garcia-Saenz JA, Pereira JR, Prabhash K, Ciuleanu TE, Kanarev V, Wang H, Balakumaran A, Jacobs I. Overall survival improvement in patients with lung cancer and bone metastases treated by denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol 2012, 7(12):1823-1829. 10.1097/JTO.0b013e31826aec2b, 23154554.
30. Hirano Y, Oda M, Tsunezuka Y, Ishikawa N, Watanabe G. Long-term survival cases of lung cancer presented as solitary bone metastasis. Ann Thorac Cardiovasc Surg 2005, 11:401-404.
31. Okamoto T, Maruyama R, Shoji F, Asoh H, Ikeda J, Miyamoto T, Nakamura T, Miyake T, Ichinose Y. Long-term survivors in stage IV non-small-cell-lung cancer. Lung Cancer 2005, 47:85-91. 10.1016/j.lungcan.2004.06.006, 15603858.
32. Collaud S, Stahel R, Inci I, Hillinger S, Schneiter D, Kestenholz P, Weder W. Survival of patients treated surgically for synchronous single-organ metastatic NSCLC and advanced pathologic TN stage. Lung Cancer 2012, 3:234-8.
33. Wang XS, Rhines LD, Shiu AS, Yang JN, Selek U, Gning I, Liu P, Allen PK, Azeem SS, Brown PD, Sharp HJ, Weksberg DC, Cleeland CS, Chang EL. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. Lancet Oncol 2012, 13:395-402. 10.1016/S1470-2045(11)70384-9, 3605896, 22285199.
34. Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 2012, 83:878-886. 10.1016/j.ijrobp.2011.08.036, 22172903.